Pliant Therapeutics, Inc. (PLRX)
Automate Your Wheel Strategy on PLRX
With Tiblio's Option Bot, you can configure your own wheel strategy including PLRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PLRX
- Rev/Share 0.0
- Book/Share 4.2005
- PB 0.3262
- Debt/Equity 0.234
- CurrentRatio 11.034
- ROIC -0.7402
- MktCap 84099231.0
- FreeCF/Share -2.8864
- PFCF -0.4759
- PE -0.3821
- Debt/Assets 0.1745
- DivYield 0
- ROE -0.6756
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | PLRX | Needham | Buy | Hold | -- | -- | March 4, 2025 |
| Resumed | PLRX | Cantor Fitzgerald | -- | Neutral | -- | -- | March 4, 2025 |
| Downgrade | PLRX | Leerink Partners | Outperform | Market Perform | -- | -- | March 3, 2025 |
| Downgrade | PLRX | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Downgrade | PLRX | Citigroup | Buy | Neutral | $40 | $4 | Feb. 10, 2025 |
| Downgrade | PLRX | Wells Fargo | Overweight | Equal Weight | $41 | $4 | Feb. 10, 2025 |
| Downgrade | PLRX | H.C. Wainwright | Buy | Neutral | -- | -- | Feb. 10, 2025 |
| Downgrade | PLRX | RBC Capital Mkts | Outperform | Sector Perform | $45 | $4 | Feb. 10, 2025 |
| Downgrade | PLRX | JP Morgan | Overweight | Neutral | -- | -- | Feb. 10, 2025 |
| Downgrade | PLRX | Canaccord Genuity | Buy | Hold | $43 | $4 | Feb. 10, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
Published: April 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
Published: April 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
PLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Pliant Therapeutics: An Activist On Deck
Published: April 03, 2025 by: Seeking Alpha
Sentiment: Negative
Pliant Therapeutics suffered a major setback with its lead drug candidate, causing its stock to plummet well below its cash value. Activist investor Kevin Tang has acquired a significant stake in PLRX, aiming to capitalize on the company's large cash reserves. Tang's history of acquiring biotechs at a discount suggests a potential profitable takeover of PLRX, despite management's defensive "poison pill" strategy.
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Published: March 28, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , March 28, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pliant Therapeutics, Inc. ("Pliant" or the "Company") (NASDAQ: PLRX).
Read More
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Pliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Published: March 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX
Published: March 04, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
Published: March 03, 2025 by: Benzinga
Sentiment: Negative
On Monday, Pliant Therapeutics Inc. PLRX announced that it would discontinue the BEACON-IPF Phase 2b trial, which evaluated bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).
Read More
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, Pliant has discontinued the BEACON-IPF Phase 2b trial evaluating bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). While an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuation of the trial, early evidence of efficacy on the forced vital capacity (FVC) endpoint was also observed.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ:PLRX). Investors who purchased Pliant securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PLRX.
Read More
PLRX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Pliant Therapeutics, Inc. investment
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Investors Who Lost Money on Pliant Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - PLRX
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ:PLRX). Investors who purchased Pliant securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PLRX.
Read More
Pliant Therapeutics, Inc. Being Investigated on Behalf of Pliant Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
Levi & Korsinsky Reminds Shareholders of an Investigation into Pliant Therapeutics, Inc. (PLRX) Regarding Potential Securities Fraud Allegations
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Feb. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ: PLRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pliant Therapeutics, Inc. (PLRX) Regarding Possible Securities Fraud Violations
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ:PLRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ:PLRX). Investors who purchased Pliant securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PLRX.
Read More
Did Pliant Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PLRX
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ:PLRX). Investors who purchased Pliant securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PLRX.
Read More
Levi & Korsinsky Reminds Shareholders of an Investigation into Pliant Therapeutics, Inc. (PLRX) Regarding Potential Securities Fraud Allegations
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
Read More
The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ:PLRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Investors to Inquire about Securities Investigation
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ:PLRX). Investors who purchased Pliant securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PLRX.
Read More
All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
PLIANT THERAPT (PLRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Reach Out
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ:PLRX). Investors who purchased Pliant securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PLRX.
Read More
About Pliant Therapeutics, Inc. (PLRX)
- IPO Date 2020-06-03
- Website https://pliantrx.com
- Industry Biotechnology
- CEO Dr. Bernard Coulie M.B.A., M.D., Ph.D.
- Employees 171